Print this page
-
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Protocol: 192204Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Other Male Genital
Larynx
Other Female Genital
Cervix
Anus
Lip, Oral Cavity and Pharynx -
Biospecimen Procurement for Cancer Immunotherapy at Rutgers Cancer Institute.
Protocol: 192002Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies.
Protocol: 092205Principal Investigator:
- Sarah Weiss MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Melanoma, Skin -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 2, Randomized, Open-Label Three-Arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) that Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 inhibitors).
Protocol: 032101Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx
Larynx